These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23141810)

  • 1. Into the future: diversifying lipid management.
    Tonkin AM; Watts GF
    Lancet; 2012 Dec; 380(9858):1971-4. PubMed ID: 23141810
    [No Abstract]   [Full Text] [Related]  

  • 2. Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution.
    Davidson MH
    Nat Rev Cardiol; 2013 Nov; 10(11):618-9. PubMed ID: 24019032
    [No Abstract]   [Full Text] [Related]  

  • 3. Beyond anti-PCSK9 therapies: the potential role of resistin inhibitors.
    Sahebkar A
    Nat Rev Cardiol; 2014 Jan; 11(1):12. PubMed ID: 24217159
    [No Abstract]   [Full Text] [Related]  

  • 4. PCSK9 inhibition: the next statin?
    Vogel RA
    J Am Coll Cardiol; 2012 Jun; 59(25):2354-5. PubMed ID: 22465426
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.
    Giugliano RP; Desai NR; Kohli P; Rogers WJ; Somaratne R; Huang F; Liu T; Mohanavelu S; Hoffman EB; McDonald ST; Abrahamsen TE; Wasserman SM; Scott R; Sabatine MS;
    Lancet; 2012 Dec; 380(9858):2007-17. PubMed ID: 23141813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antibodies in addition to statin therapy lowers LDL cholesterol].
    Bossenmayer S
    Dtsch Med Wochenschr; 2012 Sep; 137(36):1728. PubMed ID: 23281534
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels.
    Betteridge DJ
    Nat Rev Endocrinol; 2013 Feb; 9(2):76-8. PubMed ID: 23296165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finding the Right Price for Improving Care.
    Charlton B
    JAMA Intern Med; 2016 Jan; 176(1):109. PubMed ID: 26662340
    [No Abstract]   [Full Text] [Related]  

  • 11. [In addition to atorvastatin. Innovative antibody lowers LDL around 72%].
    Einecke D
    MMW Fortschr Med; 2012 Apr; 154(7):28. PubMed ID: 22558865
    [No Abstract]   [Full Text] [Related]  

  • 12. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
    Tice JA; Kazi DS; Pearson SD
    JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
    Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
    JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.
    Everett BM; Smith RJ; Hiatt WR
    N Engl J Med; 2015 Oct; 373(17):1588-91. PubMed ID: 26444323
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lowering plasma cholesterol by raising LDL receptors--revisited.
    Young SG; Fong LG
    N Engl J Med; 2012 Mar; 366(12):1154-5. PubMed ID: 22435375
    [No Abstract]   [Full Text] [Related]  

  • 17. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial.
    Roth EM; Taskinen MR; Ginsberg HN; Kastelein JJ; Colhoun HM; Robinson JG; Merlet L; Pordy R; Baccara-Dinet MT
    Int J Cardiol; 2014 Sep; 176(1):55-61. PubMed ID: 25037695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [PCSK9 inhibitors. A new approach for treatment of hypercholesterolemia].
    Saußele T
    Med Monatsschr Pharm; 2015 Jul; 38(7):250-7. PubMed ID: 26364362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alirocumab (Praluent) to lower LDL-Cholesterol.
    Med Lett Drugs Ther; 2015 Aug; 57(1475):113-5. PubMed ID: 26262881
    [No Abstract]   [Full Text] [Related]  

  • 20. Winner by points?--LDL cholesterol as a target for therapeutic intervention.
    Tietge UJ
    Curr Opin Lipidol; 2013 Jun; 24(3):277-8. PubMed ID: 23652473
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.